About the Company
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALRN News
Aileron Therapeutics Announces CEO Transition
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead ...
Aileron Therapeutics, Inc. (ALRN)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Aileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor Replacement
Aileron Therapeutics, Inc. (ALRN), a biopharma company, Tuesday announced the stepping down of Chief Executive Officer, Manuel ...
Aileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor Replacement
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), a biopharma company, Tuesday announced the stepping down of Chief Executive Officer, Manuel Aivado. He will be replaced by current Chief Operating ...
Aileron Therapeutics Inc ALRN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Aileron Therapeutics, Inc. Common Stock (ALRN)
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...
Aileron Therapeutics Inc (015.BE)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Aileron Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Aileron Therapeutics, Inc. (ALRN)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...